Search Results 821-830 of 17875 for Assay

  1. Clinical trials - Oncology (Medical)

    cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR). Rochester, Minn. The purpose of this ...

  2. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

    Serum FLC assay result with an involved FLC level ≥ 10 mg/dL (≥ 100 milligram per liter [mg/L]), provided the serum FLC ratio is abnormal. Eastern ...

  3. Publications - Eunhee S. Yi, M.D. - Mayo Clinic

    Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer ...

  4. A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer - Mayo Clinic

    Biopsy evaluable for expression of PD-L1 as determined by a PD-L1 Immunohistochemistry (IHC) pharma diagnostic test (pharmDx) assay performed by a central ...

  5. A Study of the Effect of Vedolizumab in Conjunction with Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis - Mayo Clinic

    Stoma; Disease limited to the rectum (ulcerative proctitis); Current total parenteral nutrition; Positive Clostridium difficile stool assay; History of an ...

  6. Clinical trials - Oncology (Medical)

    ... assayed from blood of cases with CAP and controls without history of cancer. DALY 2.0 USA/​ MB-CART2019.1 for DLBCL. Rochester, Minn., Scottsdale/Phoenix ...

  7. Myelin Regeneration - Neuroregeneration and Neurorehabilitation - Projects

    Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.

  8. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

    explorative studies. 4. The IDH mutation, and other applicable gene/molecular alterations (see Table 10-2) are determined by a validated assay as performed in ...

  9. Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer - Mayo Clinic

    Patients must have a potential germline mutation, as determined by the NCI-MATCH tumor profiling assay; Patients must be able to speak English and hear by ...

  10. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma - Mayo Clinic

    Serum free light chain (FLC) assay: Involved FLC level ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65) 5. Resolved acute effects of ...